1.
Dedeilia A, Lwin T, Li S, et al. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma. Annals of surgical oncology. 2023. doi:10.1245/s10434-023-14724-5.
1.
Talwar J V, Laub D, Pagadala MS, et al. Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility. American journal of human genetics. 2023. doi:10.1016/j.ajhg.2023.05.013.
1.
Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53(3):332-341. doi:10.1038/s41588-021-00779-1.
1.
Oliveira G, Stromhaug K, Cieri N, et al. Landscape of helper and regulatory antitumour CD4 T cells in melanoma. Nature. 2022;605(7910):532-538. doi:10.1038/s41586-022-04682-5.
1.
Hodis E, Triglia ET, Kwon JYH, et al. Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment. Science. 2022;376(6592):eabi8175. doi:10.1126/science.abi8175.
1.
Hu Z, Anandappa AJ, Sun J, et al. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018;132(18):1911-1921. doi:10.1182/blood-2018-04-843763.
1.
Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537-542. doi:10.1038/nature23477.
1.
Robertson G, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017;32(2):204-220.e15. doi:10.1016/j.ccell.2017.07.003.
1.
Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w.
1.
Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711.